Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
New MOA Challenges<br />
71<br />
The identification and validation of imaging biomarkers for chronic pain<br />
have lagged behind areas such as oncology, cardiovascular medicine, and<br />
neurology. The Imaging Consortium for Drug Development (ICD) should<br />
help <strong>the</strong> field of pain catch up.<br />
https://meitner.mclean.harvard.edu/<br />
The Imaging Consortium for Drug Development (ICD) is a<br />
collaborative research effort between academia and<br />
pharmaceutical companies who are developing novel drugs to<br />
treat central nervous system (CNS) disorders. The ICD uses<br />
functional MRI (fMRI) to elucidate <strong>the</strong> effects of pain<br />
modulating drugs on neural activity within <strong>the</strong> brain in humans<br />
and in animal models of CNS disease. This landmark effort<br />
builds on more than a decade of fMRI research into <strong>the</strong> study<br />
of pain, and realizes <strong>the</strong> benefits of standardization and costsharing<br />
among consortium members, for pre-competitive<br />
Neuroscience research.<br />
© Defined Health, 2009<br />
Pain Insight Briefing
Change language